{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"289"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"292"}],"units":"Participants"}],"description":"Successful sustained engraftment is defined as primary neutrophil engraftment by day 42 and e90% donor cells at day 100, with or without DLI.\n\nEngraftment based on absolute neutrophil count of donor origin \\> 0.5 x 10e9 /L for 3 days by day 42","groups":[{"description":"Patients with refractory leukemia or MDS","id":"OG000","title":"High Risk Patients"},{"description":"Patients with Disease criteria: Acute myelogenous leukemia , Acute lymphocytic leukemia, Chronic myelogenous leukemia , NHL, Hodgkins, chronic lymphocytic leukemia, multiple myeloma, Acquired bone marrow failure syndromes, Myelodysplastic syndrome, Renal cell cancer,Chronic myeloproliferative disorder","id":"OG001","title":"Standard Risk Patients"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 42 and Day 100","title":"Neutrophil and Donor Cell Engraftment","type":"PRIMARY","unitOfMeasure":"Participants"}